Homepage

Driving groundbreaking research. Improving lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

MPNRF By the Numbers

$ 0 MM
MPN RESEARCH FUNDED
0
RESEARCHERS SUPPORTED
0
PROJECTS FUNDED

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • MPN News from 2022 EHA Congress

    MPN NEWS | June 27, 2022

    A number of important findings regarding MPNs were featured in June, at the European Hematology Association’s (EHA2022) Congress in Vienna. Some key highlights follow. How to select patients with myelofibrosis for transplantation and how to manage MF patients during a transplant procedure.   Related abstract: Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?   Jean Jacques… Read More »MPN News from 2022 EHA Congress

    READ MORE

    MPN News from 2022 ASCO

    MPN NEWS | June 27, 2022

    A number of important findings regarding MPNs were featured in June, at the 2022 American Society of Clinical Oncology (2022ASCO) Annual Meeting in Chicago. Some key highlights follow. Rusfertide Shown to Reduce Phlebotomy “The target in treating patients with PV (polycythemia vera) is to chronically maintain adequate hematocrit levels below 45 percent, which reduces the… Read More »MPN News from 2022 ASCO

    READ MORE

    Identifying and Validating Actionable Biomarkers in MPN  

    MPN NEWS | May 25, 2022

    Research Spotlight on Rebekka Schneider, MD, Director, Department of Cell and Tumor Biology, Aachen University, Germany, and Erasmus MC Cancer Institute, The Netherlands. In MPNs, your blood forming stem cell acquires a mutation, and this leads to more proliferation. In the beginning, you have too many blood cells. Then, in the course of the disease,… Read More »Identifying and Validating Actionable Biomarkers in MPN  

    READ MORE
  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With your generous gift, you can change a MPN patient’s prognosis.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.

    DONATE NOW

    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get our monthly update,
    Under the Microscope